capsule and bladder mucosa anteriorly (third step). Perioperative data including operative time (OT), hospital stay (HS) and need of bladder irrigation (CBI) were analyzed. The CBI was maintained until no hematuria could be detected. The urinary scores were re-assessed 3 months after the procedure and complications were rated using the Clavien-Dindo method. The follow-up was 3 months. For statistical comparisons, the student t-test, Mann-Whitney and x2 tests were conducted using R software (version 3.4.2).
INTRODUCTION AND OBJECTIVES:
Holmium laser enucleation of the prostate (HoLEP) has become a therapeutic mainstay for prostatic obstruction, particularly for larger glands. The technique has been found to be durable and effective despite some limitations such as operative time and learning curve. The Moses laser fiber produced by Lumenis (Yokneam, Israel) is a novel technology that provides more efficient energy delivery to a target structure by decreasing water absorption of the beam. Though prior research has shown benefit of the technology as applied to stone surgery, there have been no reports of utilizing the Moses laser for prostatic enucleation. We sought to subjectively evaluate Moses laser enucleation of the prostate (MoLEP) as a novel alteration to HoLEP. METHODS: Prostatic enucleation was performed in a single patient by a single surgeon. The prostate was removed in two sections, divided by left and right prostatic lobes. Traditional holmium laser was used for the patient's right lobe, while the Moses technology was applied to the left. Subjective evaluation of the Moses laser was compared to traditional holmium laser for four critical steps of the procedure: mucosal incision, enucleation, vaporization, and hemostasis.
RESULTS: Moses technology was found to be feasible and effective for prostatic enucleation. In this single patient, mucosal incision and enucleation showed some possible increased separation of tissue, though the technique was at least equivalent to traditional HoLEP. Notably, MoLEP provided for a perceived increase in tissue vaporization and hemostasis. Overall, the surgical procedure was successful and patient progressed well postoperatively, passing a voiding trial on the first postoperative day.
CONCLUSIONS: MoLEP is feasible and effective as a treatment for benign prostatic hypertrophy. Technically, it seems to be at least equivalent to traditional HoLEP in terms of mucosal incision and enucleation with some advantages in tissue vaporization and hemostasis. More studies required to evaluate both operative and clinical outcomes, as well as how the technology may impact learning curve.
Source of Funding: none

V02-09 SINGLE-PORT ROBOT-ASSISTED RENAL TRANSPLANT: INITIAL PRE-CLINICAL EXPERIENCE USING THE SP SURGICAL SYSTEM
Mohamed Eltemamy*, Juan Garisto, Riccardo Bertolo, Alvin Wee, Jihad Kaouk, Cleveland, OH
INTRODUCTION AND OBJECTIVES:
While open surgery remains the gold standard, minimally invasive surgery has recently gained interest for kidney transplantation. The recently FDA approved da Vinci SP (Intuitive Surgical, Sunnyvale, CA) surgical system was developed specifically to facilitate single-site, multi-quadrant surgery. We aimed to report our initial pre-clinical experience using the SP surgical system (Intuitive Surgical, Sunnyvale, Ca) for kidney transplantation.
METHODS: A male fresh cadaver model was used. The GelPoint advanced access platform was placed through a 3-cm midline incision, 4 cm cephalad the belly button. A left kidney was obtained from the local procurement organization. Bench preparation of the nephrectomized kidney was performed and the kidney was introduced into the abdominal cavity through the Alexis wound protector. Then the robot was docked, and the pelvic fossa was targeted. The standardized steps of robotic multi-arm kidney transplant were duplicated.The procedure was successful with no intraoperative complications. Total operative time was 180 minutes, with 15 minutes spent for docking. 35 minutes were counted for bench surgery.
RESULTS: The procedure was successful with no intraoperative complications. Total operative time was 180 minutes, with 15 minutes spent for docking. 35 minutes were counted for bench kidney surgery.
CONCLUSIONS: Robotic Single-Port kidney transplantation using the SP surgical platform is feasible. The platform could be particularly interesting for multi-quadrant surgery such as autotransplantation, potentially reducing the time for redocking.
Source of Funding: None.
V02-10 ROBOT-ASSISTED SIMPLE PROSTATECTOMY: ILLUSTRATION OF A SIMPLIFIED EXTRAPERITONEAL, TRANSCAPSULAR TECHNIQUE
Pratik Gurung*, Prabhakar Mithal, Diane Lu, Ahmed Ghazi, Jean Joseph, Rochester, NY INTRODUCTION AND OBJECTIVES: Robot-assisted simple prostatectomy (RASP) performed with the extraperitoneal (EP) technique (EP-RASP) minimizes the risk of bowel injury, particularly when bowel adhesions are expected with entry in the transperitoneal space. However, there is a perception of its technical difficulty owing to the limited space that can be expanded within the space of Retzius. In this video, we describe the step-by-step approach of our EP-RASP technique.
METHODS: From January 2010 to July 2018, 33 consecutive patients who had undergone EP-RASP were identified from our institutional database. Procedures were performed as described in the accompanying video. A 3-cm para-umbilical incision is carried down to the anterior rectus sheath, in which a 1-cm incision is made. The underlying rectus muscle is pushed laterally, with entry into the EP space. Using a balloon dilator and a blunt-tipped trocar, the space of Retzius is further developed to allow placement of additional trocars. A transverse capsulotomy, approximately 2cm from the bladder neck, is performed a la Millin 0 s. Prostate adenoma is resected circumferentially. After ensuring hemostasis, the posterior bladder neck is sutured to the prostatic fossa, with subsequent closure of the capsulotomy. A 22Fr, 3-way Foley catheter is placed. A drain is left in the retropubic space. Patient is discharged within 1-2 days with the catheter in situ, which is then removed 10 days later. 
